Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant

M. Eapen, S. A. Giralt, M. M. Horowitz, J. P. Klein, J. E. Wagner, M. J. Zhang, M. S. Tallman, D. I. Marks, B. M. Camitta, R. E. Champlin, O. Ringdén, C. N. Bredeson, R. Martino, R. P. Gale, M. S. Cairo, Mark R Litzow, M. deLima

Research output: Contribution to journalArticle

153 Citations (Scopus)

Abstract

Treatment options for persons with leukemia relapsing after allogeneic transplantation are limited. We analyzed the outcome of 279 patients with acute and chronic leukemia, who relapsed after HLA-identical sibling transplantation and received a second allogeneic transplant. The influence of potential risk factors on treatment-related mortality (TRM), relapse, treatment failure (relapse or death) and overall survival after second transplantation were assessed using proportional-hazards regression. The cumulative incidences (95% confidence interval) of relapse and TRM at 5 years were 42 (36-48)% and 30 (24-36)%, respectively. The 5-year probabilities of both overall and leukemia-free survival were 28 (23-34)%. In multivariate analyses, risks of treatment failure and mortality were lower in younger patients (≤20 years) and patients who relapsed after 6 months from first transplantation. Risks of relapse were lower in patients who relapsed after 6 months from first transplantation and in complete remission prior to second transplantation. Risks of relapse were higher after reduced-intensity conditioning regimens. Any potential advantage of using a different matched related donor for a second transplantation is not supported by these data. Although age, disease status and conditioning regimen are important, duration of remission after first transplantation appear to be the most important determinant of outcome.

Original languageEnglish (US)
Pages (from-to)721-727
Number of pages7
JournalBone Marrow Transplantation
Volume34
Issue number8
DOIs
StatePublished - Oct 2004

Fingerprint

Siblings
Leukemia
Transplantation
Transplants
Recurrence
Treatment Failure
Mortality
Survival
Homologous Transplantation
Therapeutics
Multivariate Analysis
Tissue Donors
Confidence Intervals
Incidence

Keywords

  • Duration of remission
  • Leukemia
  • Matched related donor
  • Reduced-intensity conditioning regimen
  • Second transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Eapen, M., Giralt, S. A., Horowitz, M. M., Klein, J. P., Wagner, J. E., Zhang, M. J., ... deLima, M. (2004). Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplantation, 34(8), 721-727. https://doi.org/10.1038/sj.bmt.1704645

Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. / Eapen, M.; Giralt, S. A.; Horowitz, M. M.; Klein, J. P.; Wagner, J. E.; Zhang, M. J.; Tallman, M. S.; Marks, D. I.; Camitta, B. M.; Champlin, R. E.; Ringdén, O.; Bredeson, C. N.; Martino, R.; Gale, R. P.; Cairo, M. S.; Litzow, Mark R; deLima, M.

In: Bone Marrow Transplantation, Vol. 34, No. 8, 10.2004, p. 721-727.

Research output: Contribution to journalArticle

Eapen, M, Giralt, SA, Horowitz, MM, Klein, JP, Wagner, JE, Zhang, MJ, Tallman, MS, Marks, DI, Camitta, BM, Champlin, RE, Ringdén, O, Bredeson, CN, Martino, R, Gale, RP, Cairo, MS, Litzow, MR & deLima, M 2004, 'Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant', Bone Marrow Transplantation, vol. 34, no. 8, pp. 721-727. https://doi.org/10.1038/sj.bmt.1704645
Eapen, M. ; Giralt, S. A. ; Horowitz, M. M. ; Klein, J. P. ; Wagner, J. E. ; Zhang, M. J. ; Tallman, M. S. ; Marks, D. I. ; Camitta, B. M. ; Champlin, R. E. ; Ringdén, O. ; Bredeson, C. N. ; Martino, R. ; Gale, R. P. ; Cairo, M. S. ; Litzow, Mark R ; deLima, M. / Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. In: Bone Marrow Transplantation. 2004 ; Vol. 34, No. 8. pp. 721-727.
@article{281d27c95ab44bcca91ba0fccfb398af,
title = "Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant",
abstract = "Treatment options for persons with leukemia relapsing after allogeneic transplantation are limited. We analyzed the outcome of 279 patients with acute and chronic leukemia, who relapsed after HLA-identical sibling transplantation and received a second allogeneic transplant. The influence of potential risk factors on treatment-related mortality (TRM), relapse, treatment failure (relapse or death) and overall survival after second transplantation were assessed using proportional-hazards regression. The cumulative incidences (95{\%} confidence interval) of relapse and TRM at 5 years were 42 (36-48){\%} and 30 (24-36){\%}, respectively. The 5-year probabilities of both overall and leukemia-free survival were 28 (23-34){\%}. In multivariate analyses, risks of treatment failure and mortality were lower in younger patients (≤20 years) and patients who relapsed after 6 months from first transplantation. Risks of relapse were lower in patients who relapsed after 6 months from first transplantation and in complete remission prior to second transplantation. Risks of relapse were higher after reduced-intensity conditioning regimens. Any potential advantage of using a different matched related donor for a second transplantation is not supported by these data. Although age, disease status and conditioning regimen are important, duration of remission after first transplantation appear to be the most important determinant of outcome.",
keywords = "Duration of remission, Leukemia, Matched related donor, Reduced-intensity conditioning regimen, Second transplantation",
author = "M. Eapen and Giralt, {S. A.} and Horowitz, {M. M.} and Klein, {J. P.} and Wagner, {J. E.} and Zhang, {M. J.} and Tallman, {M. S.} and Marks, {D. I.} and Camitta, {B. M.} and Champlin, {R. E.} and O. Ringd{\'e}n and Bredeson, {C. N.} and R. Martino and Gale, {R. P.} and Cairo, {M. S.} and Litzow, {Mark R} and M. deLima",
year = "2004",
month = "10",
doi = "10.1038/sj.bmt.1704645",
language = "English (US)",
volume = "34",
pages = "721--727",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant

AU - Eapen, M.

AU - Giralt, S. A.

AU - Horowitz, M. M.

AU - Klein, J. P.

AU - Wagner, J. E.

AU - Zhang, M. J.

AU - Tallman, M. S.

AU - Marks, D. I.

AU - Camitta, B. M.

AU - Champlin, R. E.

AU - Ringdén, O.

AU - Bredeson, C. N.

AU - Martino, R.

AU - Gale, R. P.

AU - Cairo, M. S.

AU - Litzow, Mark R

AU - deLima, M.

PY - 2004/10

Y1 - 2004/10

N2 - Treatment options for persons with leukemia relapsing after allogeneic transplantation are limited. We analyzed the outcome of 279 patients with acute and chronic leukemia, who relapsed after HLA-identical sibling transplantation and received a second allogeneic transplant. The influence of potential risk factors on treatment-related mortality (TRM), relapse, treatment failure (relapse or death) and overall survival after second transplantation were assessed using proportional-hazards regression. The cumulative incidences (95% confidence interval) of relapse and TRM at 5 years were 42 (36-48)% and 30 (24-36)%, respectively. The 5-year probabilities of both overall and leukemia-free survival were 28 (23-34)%. In multivariate analyses, risks of treatment failure and mortality were lower in younger patients (≤20 years) and patients who relapsed after 6 months from first transplantation. Risks of relapse were lower in patients who relapsed after 6 months from first transplantation and in complete remission prior to second transplantation. Risks of relapse were higher after reduced-intensity conditioning regimens. Any potential advantage of using a different matched related donor for a second transplantation is not supported by these data. Although age, disease status and conditioning regimen are important, duration of remission after first transplantation appear to be the most important determinant of outcome.

AB - Treatment options for persons with leukemia relapsing after allogeneic transplantation are limited. We analyzed the outcome of 279 patients with acute and chronic leukemia, who relapsed after HLA-identical sibling transplantation and received a second allogeneic transplant. The influence of potential risk factors on treatment-related mortality (TRM), relapse, treatment failure (relapse or death) and overall survival after second transplantation were assessed using proportional-hazards regression. The cumulative incidences (95% confidence interval) of relapse and TRM at 5 years were 42 (36-48)% and 30 (24-36)%, respectively. The 5-year probabilities of both overall and leukemia-free survival were 28 (23-34)%. In multivariate analyses, risks of treatment failure and mortality were lower in younger patients (≤20 years) and patients who relapsed after 6 months from first transplantation. Risks of relapse were lower in patients who relapsed after 6 months from first transplantation and in complete remission prior to second transplantation. Risks of relapse were higher after reduced-intensity conditioning regimens. Any potential advantage of using a different matched related donor for a second transplantation is not supported by these data. Although age, disease status and conditioning regimen are important, duration of remission after first transplantation appear to be the most important determinant of outcome.

KW - Duration of remission

KW - Leukemia

KW - Matched related donor

KW - Reduced-intensity conditioning regimen

KW - Second transplantation

UR - http://www.scopus.com/inward/record.url?scp=6444220659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6444220659&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704645

DO - 10.1038/sj.bmt.1704645

M3 - Article

C2 - 15322568

AN - SCOPUS:6444220659

VL - 34

SP - 721

EP - 727

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 8

ER -